• Deniz Kizilay, Didem Dal, Kemal T Saracoglu, Zeynep Eti, and Fevzi Y Gogus.
• Department of Anesthesiology, Marmara University Medical School, Istanbul, Turkey. Electronic address: denizkizilay@yahoo.com.
• J Clin Anesth. 2016 Feb 1; 28: 30-5.

Study ObjectiveThe aim of this study is to compare the hemodynamic effects of neostigmine-atropine combination and sugammadex in patients with cardiac problems undergoing noncardiac surgery.DesignProspective randomized study.SettingIn the operating room.PatientsNinety patients with a class 2 or 3 cardiovascular disease according to the New York Heart Association classification and aged between 18 and 75 years undergoing noncardiac surgery were randomized.InterventionsGroup N (n = 45) received 0.03 mg/kg IV neostigmine when T2 appeared as measured with a nerve muscle stimulator. When heart rate was 5 beats/min (±10 beats/min) lower than the heart rate before administration of the medication, 0.5 mg IV atropine sulfate was given. Group S (n = 45) received 3 mg/kg IV sugammadex when T2 appeared as measured with a nerve muscle stimulator.MeasurementsHeart rate, mean systolic and diastolic blood pressures, and electrocardiographic alterations including the QTc (QT Fredericia and QT Bazett) were recorded.Main ResultsThere were no significant differences between and within the groups in terms of QTc values. Sugammadex group had a significant decrease on heart rate 1 minute after the medication when compared to the measurement before the medication (P < .05). Heart rate and systolic blood pressure increased in neostigmine group 3 minutes after the medication and during postoperative measurements (P < .05). Sugammadex group had lower systolic, diastolic, and mean blood pressures and heart rate when compared to neostigmine group (P < .05).ConclusionsWe suggest that sugammadex might be preferred as it provides more hemodynamic stability compared to neostigmine-atropine combination to reverse rocuronium-induced neuromuscular blockage in cardiac patients undergoing noncardiac surgery.Copyright © 2016 Elsevier Inc. All rights reserved.

34 keywords...

hide…